SRC activity has previously been linked to resistance to anti-HER2 therapies, with SRC activation correlating with trastuzumab resistance in breast cancer cells, and overexpression of an activated mutant form of SRC (Y527F) resulted in resistance to trastuzumab-mediated growth inhibition [40]. Here, ERBB2 is linked to breast cancer.